Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis
Citation
Meltzer , E , Ratner , P , Bachert , C , Carr , W , Berger , W , Canonica , G W , Hadley , J , Lieberman , P , Hampel , F C , Mullol , J , Munzel , U , Price , D , Scadding , G , Virchow , J C , Wahn , U , Murray , R & Bousquet , J 2013 , ' Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis ' , International Archives of Allergy and Immunology , vol. 161 , no. 4 , pp. 369-377 . https://doi.org/10.1159/000351404
Rights
© 2013 S. Karger AG, Basel. This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercialNoDerivs 3.0 License (www.karger.com/OA-license), applicable to the online version of the article only. Distribution for non-commercial purposes only https://creativecommons.org/licenses/by-nc-nd/4.0/